Related Experiment Videos
Anti-IgE therapy in allergic disease
1National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver, Colorado 80206, USA. milgromh@njc.org
Current Opinion in Pediatrics
|November 19, 2004
Summary
Recombinant anti-immunoglobulin E (anti-IgE) therapy effectively controls allergic disorders by reducing IgE levels and inflammation. Clinical studies show improved asthma control with fewer exacerbations and reduced medication needs.
Area of Science:
- Immunology
- Allergy Research
- Pharmacology
Background:
- Allergic disorders are mediated by immunoglobulin E (IgE).
- Current treatments for allergic diseases have limitations.
- Recombinant monoclonal humanized anti-IgE offers a novel therapeutic approach.
Purpose of the Study:
- To review clinical data on anti-IgE in asthma, allergic rhinitis, and food allergy.
- To evaluate the role of anti-IgE in current asthma treatment strategies.
Main Methods:
- Review of recent clinical studies involving anti-IgE therapy.
- Analysis of anti-IgE's impact on IgE levels and allergic responses.
- Examination of anti-IgE's effects on inflammatory markers and cell expression.
Main Results:
- Anti-IgE therapy significantly reduces free IgE and inhibits allergic reactions.
- In moderate to severe asthma, anti-IgE decreases exacerbations and corticosteroid/beta-agonist use.
- Anti-IgE reduces Fc epsilon RI expression, tissue eosinophils, lymphocytes, and IL-4 positive cells.
Conclusions:
- Clinical anti-IgE studies advance understanding of IgE-mediated diseases.
- Anti-IgE is effective in treating allergic diseases.
- Further research is needed to optimize clinical strategies and patient selection for anti-IgE therapy.